Back to Awarded Treatment Trials
Awarded Trial: 03T-459
Grant ID
03T-459
Illness
Schizophrenia
Primary Drug/Intervention
Celecoxib
Primary Dosage
400mg/day
Secondary Drug Intervention
Risperidone
Secondary Dosage
6mg/day
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Zhang
Sample Size
250
Duration of Study Period for Each Subject
24 weeks
Outcome Measurements
PANSS, BPRS, SANS, ICG, WCST, N-back Test, WMS-R, CPT, WAIS-R, FSIQ, SAS, AIMS, MANOVAs
Results
250 cases of first-episode (up to 2 years) were randomized to risperidone alone or risperidone plus celecoxib for 12 weeks. The celecoxib group showed a significant reduction in total PANSS, general psychopathology subscore, negative symptoms subscore, and HAMD total score.
Publication
N/A
Link
N/A
PI Name
Xiang Zhang
Degree
MD
Center
Department of Clinical Psychology
Institution
Beijing Hui-Long-Guan Hospital
Address
Xi San Qi, Hai Dian District
City or Town
Beijing
State or Province
N/A
Zip or Postal Code
100096
Country
China
Email Address
zhangxy9@yahoo.com